Accueil>>PAR4 (1-6) (mouse) (trifluoroacetate salt)

PAR4 (1-6) (mouse) (trifluoroacetate salt) (Synonyms: GYPGKF, H-Gly-Tyr-Pro-Gly-Lys-Phe-OH)

Catalog No.GC40156

PAR4 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 4 (PAR4; EC50 = 30 μM in Xenopus oocytes expressing human PAR4 receptors) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of mouse PAR4 and residues 60-65 of the full-length sequence.

Products are for research use only. Not for human use. We do not sell to patients.

PAR4 (1-6) (mouse) (trifluoroacetate salt) Chemical Structure

Taille Prix Stock Qté
1mg
60,00 $US
En stock
5mg
271,00 $US
En stock
10mg
479,00 $US
En stock
25mg
1 051,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PAR4 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 4 (PAR4; EC50 = 30 μM in Xenopus oocytes expressing human PAR4 receptors) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of mouse PAR4 and residues 60-65 of the full-length sequence. It induces calcium release in wild-type and PAR3-/- mouse platelets and in human platelets but has no activity in Xenopus oocytes expressing human PAR1. PAR4 (1-6) also triggers [3H]inositol phosphate release from KOLF cells expressing human PAR4.

Avis

Review for PAR4 (1-6) (mouse) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PAR4 (1-6) (mouse) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.